Abstract
Dolutegravir in combination with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has been recommended by the WHO since 2018 as first-line
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
